"The
Report PharmaPoint: Macular Edema and Macular Degeneration - Global
Drug Forecast and Market Analysis to 2023 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz
Macular
Edema is a condition where fluid accumulates on the macula, leading
to vision impairment or in severe cases even vision loss. The three
main types of ME are diabetic macular edema (DME), and macular edema
following either a central or branch retinal vein occlusion (ME-CRVO
and ME-BRVO). Age-related macular degeneration (AMD) is a painless
eye condition which leads to gradual, irreversible, loss of central
vision, and is one of the leading causes of blindness among people
aged 50 and over in the developed world. Currently the ME and AMD
markets are dominated by the use of anti-VEGF monotherapy, however,
in recent years, corticosteroid implants have been reaching the ME
market which could challenge the stronghold these drugs have in this
sector. The AMD market will see the arrival of the first therapies to
treat dry AMD, fulfilling a huge unmet need in the management of this
retinal disease, and these first-in-class therapies will strongly
drive the market growth over the next ten years. The launch of wet
AMD adjunctive therapies will also see a significant change in the
treatment of AMD patients and have a positive impact on the market
growth.
View Report At
:http://www.marketresearchreports.biz/analysis/247011
Highlights
Key Questions Answered
- The ME market has been
dominated by anti-VEGF drugs Lucentis and Avastin for many years,
however, rival drug Eylea has recently gained approval for ME
indications across the 7MM. How will this impact the positions that
Lucentis and Avastin hold in this market? How will this change over
the forecast period, and which drug will covet the leading position
in 2023?
- The current late stage AMD
pipeline is varied, with first-in-class drugs in development for both
dry AMD and wet AMD. Which of these will have the biggest impact on
the AMD market? What strategies are developers undertaking to
penetrate the wet AMD market? Will the novel dry AMD drugs fulfil the
huge unmet need for this retinal disease?
- Population aging is occurring
in almost all countries worldwide, particularly in the 7MM. This is
expected to have a significant impact on the prevalence of
age-related diseases such as AMD and conditions causing ME. How will
epidemiological changes impact the growth of the future ME and AMD
markets?
Key Findings
- The main driver of growth in
the AMD market will be the introduction of first-in-class drugs over
the forecast period. The launch of two new therapies for dry AMD will
significantly grow this market and the arrival of adjunctive
therapies for wet AMD will further strengthen this growth in the AMD
market.
- The rapid expansion of Eylea
within the ME market will lead to a shift in market leader over the
forecast period, with Lucentis losing this position to rival
anti-VEGF drug Eylea.
- The biggest barrier for
growth in the ME and AMD markets will be the increasing pressure to
show drug cost-effectiveness. This is likely to have a negative
impact on these markets, as regulatory bodies are adopting stricter
criteria for new drug approvals and reimbursement listing.
- Significant opportunities
remain for further drug development in both the ME and AMD markets as
numerous unmet needs remain, in particular the need for effective dry
AMD drugs with non-invasive formulations.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/247011
Scope
-
Overview of ME and AMD, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and treatment guidelines.
-
Annualized ME and AMD market revenue, annual cost of therapy and
treatment usage pattern data from 2013 and forecast for ten years to
2023.
-
Key topics covered include market characterization, unmet needs, R&D
and clinical trials assessment, late stage clinical trial analysis
and implications for the ME and AMD therapeutics markets.
-
Pipeline analysis: focus on the seven late-stage pipeline ME and AMD
drugs discussing emerging trends as well as overview of earlier phase
drugs.
-
Analysis of the current and future market competition in the global
ME and AMD therapeutics market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.
Reasons to buy
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the global ME and AMD therapeutics markets.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global ME and AMD therapeutics markets in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the global ME and AMD therapeutics markets from
2013-2023.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 27
2.1 Related Reports 28
3 Disease Overview 29
3.1 Macular Degeneration
Overview 29
3.1.1 Etiology and
Pathophysiology 31
3.1.2 Classification 35
3.1.3 Symptoms and Diagnosis 37
3.2 Macular Edema Overview 40
3.2.1 Etiology and
Pathophysiology 41
3.2.2 Classification 44
3.2.3 Symptoms and Diagnosis 45
4 Epidemiology - Macular Edema
48
4.1 Disease Background 48
4.2 Risk Factors and
Comorbidities 48
4.3 Global Trends 49
4.3.1 US 50
4.3.2 5EU 50
4.3.3 Japan 51
4.4 Forecast Methodology 51
4.4.1 Sources Used 52
4.4.2 Sources Not Used 54
4.4.3 Forecast Assumptions and
Methods Diagnosed Prevalent Cases of Diabetes 55
4.4.4 Forecast Assumptions and
Methods Diagnosed Prevalent Cases of Diabetic Retinopathy 59
4.4.5 Forecast Assumptions and
Methods - Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic
Retinopathy Population 60
4.4.6 Forecast Assumptions and
Methods - Total Prevalent Cases of ME following BRVO and CRVO 61
4.5 Epidemiological Forecast
for Macular Edema (2013-2023) 62
4.5.1 Diagnosed Prevalent Cases
of DME in the Diagnosed Diabetic Retinopathy Population 62
4.5.2 Age-Specific Diagnosed
Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy
Population 64
4.5.3 Sex-Specific Diagnosed
Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy
Population 66
4.5.4 Total Prevalent Cases of
ME Following BRVO 68
4.5.5 Age-Specific Total
Prevalent Cases of ME Following BRVO 70
4.5.6 Sex-Specific Total
Prevalent Cases of ME following BRVO 72
4.5.7 Total Prevalent Cases of
ME Following CRVO 74
4.5.8 Age-Specific Total
Prevalent Cases of ME Following CRVO 76
4.5.9 Sex-Specific Total
Prevalent Cases of ME Following CRVO 78
4.6 Discussion 80
4.6.1 Epidemiological Forecast
Insight 80
4.6.2 Limitations of the
Analysis 81
4.6.3 Strengths of the Analysis
82
5 Epidemiology - Age-Related
Macular Degeneration 83
5.1 Disease Background 83
5.2 Risk Factors and
Comorbidities 84
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment